Pumitamig

Phase 3Small molecule

Bristol-Myers Squibb

Pumitamig is one of 285 small molecule programs targeting Small Cell Lung Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

284

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CarcinomaRecruiting

Renal Cell CarcinomaRecruiting

Advanced Renal Cell Carcinoma (RCC)Recruiting

Hepatocellular Carcinoma (HCC)Recruiting

Cervical CancerRecruiting

Extensive-Stage Small-Cell Lung CancerRecruiting

Solid TumoursRecruiting

Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting

Non-Small Cell Lung CancerRecruiting

GlioblastomaRecruiting

Small Cell Lung CarcinomaPreclinical

Recruiting

Renal Cell CarcinomaPhase 1

Recruiting

Advanced Renal Cell Carcinoma (RCC)Preclinical

Recruiting

Hepatocellular Carcinoma (HCC)Preclinical

Recruiting

Cervical CancerPreclinical

Recruiting

Extensive-Stage Small-Cell Lung CancerPhase 3

Recruiting

Solid TumoursPreclinical

Recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)Phase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

GlioblastomaPhase 2

Recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Navmi

SSummit Therapeutics

Phase 3

7 2

Navelbine

PPierre Fabre Medicament

Phase 3

24 3

Pumitamig

Bristol-Myers Squibb

Phase 3

3 4

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Solid Tumours

NCT07160725

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07255404

Q4 2028

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT06841055

Q1 2029

Phase 3Recruiting

Extensive-Stage Small-Cell Lung Cancer

NCT06712355

Q2 2029

PreclinicalRecruiting

Small Cell Lung Carcinoma

NCT07325136

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Recruiting· BioNTech logo

BioNTech·Phase 2·NCT06841055·60 enrolled

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT06712316·1,580 enrolled

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07111520·880 enrolled

Non-small Cell Lung Cancer (NSCLC)3 trials

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07680764·160 enrolled

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT07361510·750 enrolled

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT07361497·850 enrolled

Solid Tumor2 trials

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07070232·1,438 enrolled

Metastatic Colorectal Cancer2 trials

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07221357·990 enrolled

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With Pumitamig and Chemotherapy in Participants With Metastatic Colorectal Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07079631·482 enrolled

Glioblastoma1 trial

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Recruiting· BioNTech logo

BioNTech·Phase 2·NCT07297212·75 enrolled

11 more indications

Breast Neoplasms1 trial

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

Recruiting· BioNTech logo

BioNTech·Phase 3·NCT07173751·558 enrolled

Hepatocellular Carcinoma (HCC)1 trial

ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07291076·198 enrolled

Lung Cancer1 trial

A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT06618287·416 enrolled

Small Cell Lung Carcinoma1 trial

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07325136·240 enrolled

Advanced Renal Cell Carcinoma (RCC)1 trial

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07293351·474 enrolled

Esophageal Adenocarcinoma1 trial

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07221149·690 enrolled

Extensive-stage Small-cell Lung Cancer1 trial

A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer

Recruiting· BioNTech logo

BioNTech·Phase 3·NCT06712355·621 enrolled

Cervical Cancer1 trial

A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT04895709·1,109 enrolled

Renal Cell Carcinoma1 trial

A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT07195682·281 enrolled

Solid Tumours1 trial

A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07160725·540 enrolled

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

A Phase II, Multi-site, Randomized, Open-label, Trial of Pumitamig in Combination With Chemotherapy in Patients With Metastatic Pancreatic Cancer

Recruiting· BioNTech logo

BioNTech·Phase 2·NCT07255404·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Pumitamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pumitamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pumitamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Pumitamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q1 2029

Q2 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Non-small Cell Lung Cancer (NSCLC)3 trials

Solid Tumor2 trials

Metastatic Colorectal Cancer2 trials

Glioblastoma1 trial

Breast Neoplasms1 trial

Hepatocellular Carcinoma (HCC)1 trial

Lung Cancer1 trial

Small Cell Lung Carcinoma1 trial

Advanced Renal Cell Carcinoma (RCC)1 trial

Esophageal Adenocarcinoma1 trial

Extensive-stage Small-cell Lung Cancer1 trial

Cervical Cancer1 trial

Renal Cell Carcinoma1 trial

Solid Tumours1 trial

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

References

Drug Info

Quick Facts

Related News